Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

DVD series "Start Fitness Now: Beating Type 2 Diabetes" released

NBC's "Biggest Loser" trainer Kim Lyons announces the newest addition to her fitness empire- 3 title DVD series Start Fitness Now: Beating Type 2 Diabetes and online support forum; produced and distributed by Watch It Now Entertainment.

26 Oct 2009

Aerobic activity makes older adults' arteries more elastic

Just three months of physical activity reaps heart health benefits for older adults with type 2 diabetes by improving the elasticity in their arteries - reducing risk of heart disease and stroke, Dr. Kenneth Madden told the 2009 Canadian Cardiovascular Congress, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.

26 Oct 2009

PPA reaches historic milestone; helps the six millionth person

After visiting more than 3,000 cities in all 50 states, the Partnership for Prescription Assistance (PPA) has reached a historic milestone today by helping the six millionth person at an event in Harrisburg, Pennsylvania.

24 Oct 2009

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.

23 Oct 2009

Number of diabetic patients on the rise; figures could reach to 440 million by 2030

Newly published data from the International Diabetes Federation (IDF) show that number of people with diabetes continues to grow unchecked. The figures reveal that, if action is not taken to change the path of the epidemic, the numbers of people with diabetes will be close to 440 million by 2030.

23 Oct 2009

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, today announced that it has signed a long-term multi-project research and license collaboration agreement with Roche.

23 Oct 2009

Medtronic announces ONSET trial results of sensor-enhanced CSII in children

Medtronic, Inc. today announced study results from an oral presentation at the International Diabetes Federation’s World Diabetes Congress held in Montreal, Canada. This scientific convention highlights the latest developments in clinical research aimed at improving diabetes management and outcomes.

23 Oct 2009

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

New data on patient treatment satisfaction from the LEAD(TM) 6 trial presented on the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide.

23 Oct 2009

Important guidelines from IDF for diabetes care

The Guidelines are the work of the IDF Task Force on Clinical Guidelines, which is focused on meeting the critical global need to provide up-to-date evidence-based information and training for healthcare professionals.

23 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Update from Karo Bio for the period January-September

In an update of the project portfolio, Karo Bio announced, among other things, that the company, in accordance with earlier communicated plans, has submitted an IND application for eprotirome to the American Food and Drug Administration (FDA); that a candidate drug has been nominated within the ER-beta program; and that the company has decided not to initiate further in-house development of KB3305 for the treatment of type 2 diabetes.

22 Oct 2009

Clinical performance study reveals the accuracy and precision of TRUE2go system

Home Diagnostics, Inc., a leading developer, manufacturer, and marketer of blood glucose monitoring systems, today announced the results of a TRUE2go™ clinical performance study published in the October 2009 issue of the journal Diabetes Technology & Therapeutics. The study, “Clinical Performance of the TRUE2go Blood Glucose System – A Novel Integrated System for Meter and Strips,” demonstrated the accuracy and precision of the TRUE2go system and found that it was both easy and convenient to use by patients.

22 Oct 2009

People in developing countries spend 90% of all medical expenditures for diabetes care

Type 2 diabetes is often seen as a condition affecting older, unproductive adults in wealthy countries. However, the reality is that 70% of people with diabetes now live in low and middle-income countries and the economic impact of diabetes is much greater in poorer countries.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

OSI Pharmaceuticals, Inc. announced today its financial results for the Company’s third quarter ended September 30, 2009. The Company reported total revenues from continuing operations of $111 million for the third quarter of 2009 compared to revenues of $95 million for the third quarter of 2008, an 18% increase over the prior year period.

22 Oct 2009

New findings from ADVANCE clinical trial presented

New analyses of the largest-ever clinical trial of patients with type 2 diabetes show that the combination of blood pressure lowering treatment and intensive glucose (blood sugar) control improved patients' vascular condition and resulted in a significant 18 percent reduction in the risk of death from all causes.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

New diabetes algorithm released by AACE for the management of type 2 diabetes

A new, first-of-its-kind diabetes algorithm created to help achieve glycemic (blood sugar) control in type 2 patients was published online today in the September/October edition of Endocrine Practice.

22 Oct 2009

Beth Israel Deaconess Medical Center collaborates with Navigenics to make personalized genomics available to doctors in training

Beth Israel Deaconess Medical Center and Navigenics, Inc., a leading personal genomics company, today announced a collaboration to make personalized genomics available to doctors in training.

21 Oct 2009

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

DVD series "Start Fitness Now: Beating Type 2 Diabetes" released

Aerobic activity makes older adults' arteries more elastic

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

PPA reaches historic milestone; helps the six millionth person

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Number of diabetic patients on the rise; figures could reach to 440 million by 2030

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

Medtronic announces ONSET trial results of sensor-enhanced CSII in children

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Important guidelines from IDF for diabetes care

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Update from Karo Bio for the period January-September

Clinical performance study reveals the accuracy and precision of TRUE2go system

People in developing countries spend 90% of all medical expenditures for diabetes care

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

New findings from ADVANCE clinical trial presented

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

New diabetes algorithm released by AACE for the management of type 2 diabetes

Beth Israel Deaconess Medical Center collaborates with Navigenics to make personalized genomics available to doctors in training

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in